Key facts
- This page summarizes Tuan Tu Diep's Form 4 filing for Skye Bioscience, Inc. (SKYE).
- 14 reported transactions and 14 derivative rows are listed below.
- Accepted by SEC: 02 Apr 2026, 18:07.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Disposed to Issuer
Award
Disposed to Issuer
Award
Disposed to Issuer
Award
Disposed to Issuer
Award
Disposed to Issuer
Award
Disposed to Issuer
Award
Disposed to Issuer
Additional SEC filing notes
Footnote F1
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing.
Footnote F2
The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. The grant date for the stock option is February 25, 2025. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F3
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged.
Footnote F4
The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F5
The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F6
The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 29, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F7
The stock option is fully vested.
Footnote F8
The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.